<DOC>
	<DOCNO>NCT00804076</DOCNO>
	<brief_summary>The primary purpose study examine safety NP2 ( nonreplicating HSV-based vector express enkephalin ) patient cancer pain . The secondary purpose evaluate efficacy .</brief_summary>
	<brief_title>Gene Transfer Cancer Pain</brief_title>
	<detailed_description>Therapeutic HSV-based vector deliver gene skin inoculation sensory neuron interrupt pain signal spinal level . Side effect may limit focal distribution vector delivery preproenkephalin expression . Preproenkephalin natural human gene produce peptide bind opioid receptor body . The therapeutic evaluate , NP2 , replication defective herpes simplex type 1 virus ( HSV-1 ) modify express human preproenkephalin gene demonstrate efficacy numerous model pain , include pain cause cancer .</detailed_description>
	<criteria>1 . Patients intractable pain malignant disease 5 year project survival le 25 % . 2 . Female patient childbearing potential negative pregnancy test use birth control . 3 . Patients receive recent treatment radiation , chemotherapeutic immunotherapeutic agent expect undergo treatment 28 day injection NP2 . 4 . Patients surgical stabilization/resection within 4 week Screening plan additional surgical procedure . 5 . Patients adequate bone marrow function , IgG level great 565 mg % CD4 count great 500. . 1 . Patients serious uncontrolled medical condition malignancy . 2 . Patients severe liver renal impairment 3 . Patients currently previously positive serology HIV , Hepatitis B Hepatitis C. 4 . Patients hemoglobin &lt; 9 gm % uncontrolled coagulopathy bleed diathesis . 5 . Patients clinical diagnosis active herpes infection within past 6 month . 6 . Patients vaccinate prevent HSV infection history shingle presence active shingle .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>gene therapy</keyword>
	<keyword>replication defective HSV vector</keyword>
	<keyword>pain</keyword>
	<keyword>enkephalin</keyword>
	<keyword>intradermal</keyword>
</DOC>